Amlodipin/Valsartan/HCT beta 10 mg/160 mg/25 mg Filmtabletten Německo - němčina - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

amlodipin/valsartan/hct beta 10 mg/160 mg/25 mg filmtabletten

betapharm arzneimittel gmbh (3364323) - amlodipinbesilat; valsartan; hydrochlorothiazid - filmtablette - teil 1 - filmtablette; amlodipinbesilat (24866) 13,87 milligramm; valsartan (26826) 160 milligramm; hydrochlorothiazid (00512) 25 milligramm

Amlodipin/Valsartan/HCT beta 10 mg/160 mg/12,5 mg Filmtabletten Německo - němčina - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

amlodipin/valsartan/hct beta 10 mg/160 mg/12,5 mg filmtabletten

betapharm arzneimittel gmbh (3364323) - amlodipinbesilat; valsartan; hydrochlorothiazid - filmtablette - teil 1 - filmtablette; amlodipinbesilat (24866) 13,87 milligramm; valsartan (26826) 160 milligramm; hydrochlorothiazid (00512) 12,5 milligramm

Amlodipin/Valsartan/HCT beta 5 mg/160 mg/25 mg Filmtabletten Německo - němčina - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

amlodipin/valsartan/hct beta 5 mg/160 mg/25 mg filmtabletten

betapharm arzneimittel gmbh (3364323) - amlodipinbesilat; valsartan; hydrochlorothiazid - filmtablette - teil 1 - filmtablette; amlodipinbesilat (24866) 6,935 milligramm; valsartan (26826) 160 milligramm; hydrochlorothiazid (00512) 25 milligramm

Teysuno Evropská unie - němčina - EMA (European Medicines Agency)

teysuno

nordic group b.v. - tegafur, gimeracil, oteracil - magen-neoplasmen - antineoplastische mittel - teysuno is indicated in adults:- for the treatment of advanced gastric cancer when given in combination with cisplatin (see section 5. - as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting.

Tyenne Evropská unie - němčina - EMA (European Medicines Agency)

tyenne

fresenius kabi deutschland gmbh - tocilizumab - arthritis, rheumatoid; cytokine release syndrome; arthritis, juvenile rheumatoid; covid-19 virus infection; giant cell arteritis - immunsuppressiva - tyenne, in combination with methotrexate (mtx), is indicated for- the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx. - the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists. in these patients, tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tocilizumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. tyenne is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. tyenne can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx. tyenne in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tyenne is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older. tyenne is indicated for the treatment of giant cell arteritis (gca) in adult patients.

Anastrozol AbZ 1 mg Filmtabletten Německo - němčina - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

anastrozol abz 1 mg filmtabletten

abz-pharma gmbh - geschäftsanschrift - (4238075) - anastrozol - filmtablette - teil 1 - filmtablette; anastrozol (27057) 1 milligramm

Endoxan Německo - němčina - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

endoxan

baxter oncology gmbh (8044474) - cyclophosphamid 1 h<2>o - überzogene tablette - teil 1 - überzogene tablette; cyclophosphamid 1 h<2>o (12932) 53,5 milligramm

Lorzaar Plus 50/12,5 mg Filmtabletten Německo - němčina - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

lorzaar plus 50/12,5 mg filmtabletten

organon healthcare gmbh (1007295) - hydrochlorothiazid; losartan-kalium - filmtablette - teil 1 - filmtablette; hydrochlorothiazid (00512) 12,5 milligramm; losartan-kalium (26551) 50 milligramm

LORZAAR PLUS forte 100/12,5 mg Filmtabletten Německo - němčina - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

lorzaar plus forte 100/12,5 mg filmtabletten

organon healthcare gmbh (1007295) - losartan-kalium; hydrochlorothiazid - filmtablette - teil 1 - filmtablette; losartan-kalium (26551) 100 milligramm; hydrochlorothiazid (00512) 12,5 milligramm